Paul Tudor Jones Madrigal Pharmaceuticals, Inc. Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 1,400 shares of MDGL stock, worth $474,474. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,400

Previous 3,400 58.82%

Holding current value

$474,474

Previous $952,000 68.8%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $558,323 - $922,763	3,258 New	3,258 $870,000
Q3 2023 Nov 15, 2023	BUY	$146.04 - $225.78 $215,116 - $332,573	1,473 Added 45.76%	4,692 $685,000
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $1.96 Million - $3 Million	-9,610 Reduced 74.91%	3,219 $743,000
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $1.01 Million - $1.35 Million	4,384 Added 51.91%	12,829 $3.11 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $36,026 - $182,965	617 Added 7.88%	8,445 $2.45 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $666 - $874	11 Added 0.14%	7,828 $509,000
Q2 2022 Aug 15, 2022	BUY	$58.04 - $100.2 $453,698 - $783,263	7,817 New	7,817 $560,000
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $477,077 - $869,733	-8,536 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$72.34 - $95.09 $617,494 - $811,688	8,536 New	8,536 $723,000
Q1 2020 May 15, 2020	SELL	$66.76 - $93.49 $373,121 - $522,515	-5,589 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$84.28 - $118.5 $471,040 - $662,296	5,589 New	5,589 $509,000

Others Institutions Holding MDGL

# of Institutions

296

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.8B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account